NovoCure (NVCR) Q2 2026: Patient Growth and Guidance Lift Drive Big Beat
As seen on the 24/7 Wall St. homepage on July 23, 2026.
NovoCure crushed expectations with active patients surging 18% to 5,128 and swinging to positive Adjusted EBITDA, sending the cancer therapy company to a $0.13 loss per share that beat estimates by 61%. The company lifted full-year revenue guidance to $710 million to $725 million on the strength of Optune Lua and Optune Pax, which together pulled in $7 million this quarter.
Continue ReadingShow less
NovoCure posted a loss of $0.13 per share for Q2 2026, coming in 61% better than the consensus estimate of roughly $0.33. Revenue landed at $183.6 million, about 6% above the $172.7 million analysts had expected. The company also swung to positive Adjusted EBITDA during the quarter, a meaningful step forward for a business that has been running at a loss while scaling its commercial infrastructure.
A key driver of the outperformance was patient growth: active patients rose 18% to 5,128, reflecting continued adoption of NovoCure's Tumor Treating Fields technology. The newer devices, Optune Lua and Optune Pax, contributed $7 million in combined revenue this quarter, underscoring the early commercial traction of the company's pipeline beyond its established glioblastoma indication.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
With momentum building, NovoCure raised its full-year revenue guidance to a range of $710 million to $725 million. Looking back over recent quarters, the Q2 2026 result is a sharp contrast to Q1 2026, when the company missed estimates with a loss of $0.62 per share, making the degree of sequential improvement all the more notable for investors watching the turnaround trajectory.
Mentioned: NVCR